A clearer understanding of how the Endo180 pathway regulates osteoid deposition in primary and secondary bone cancer will require its in‐depth evaluation as an anti‐osteogenic target in models that recapitulate their dominant osteosclerotic nature. Here, MRC2 is linked to bone neoplasm.